Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical
challenges due to their invasive nature and limited treatment options. The current …

High-grade gliomas, the most common and aggressive primary brain tumors, are
characterized by a complex tumor microenvironment (TME). Among the immune cells …

Given the limited sensitivity of screening methods and the lack of effective therapeutic
interventions for malignant brain tumors such as glioblastoma multiforme (also known as …

Cancer theragnostics is a novel approach that combines diagnostic imaging and
radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized …

Simple Summary Neuroimaging has transformed the way brain tumors are diagnosed and
treated. Although different non-invasive modalities provide very helpful information, in some …

Immunotherapy constitutes a paradigm shift in cancer treatment. Its FDA approval for several
indications has yielded improved prognosis for cases where traditional therapy has shown …

Cancer is one of the most severe health problems worldwide accounting for the second
leading cause of death. Studies have indicated that cancers utilize different metabolic …

Glioblastoma (GBM) is the most aggressive malignant brain tumour, with a median survival
of 3 months without treatment and 15 months with treatment. Early GBM diagnosis can …

Glioma is the most common primary intracranial malignant tumour in adults. It has a high
incidence and poses a serious threat to human health. Circular RNA is a hotspot of cancer …

Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has
experienced no changes in treatment for nearly two decades and has a 5-year survival rate …